Drug Profile
FB 101
Alternative Names: 1ST-102; 1ST102 Programme; FB-101Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator 1St Biotherapeutics
- Developer 1St Biotherapeutics; Neuraly
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Amyotrophic lateral sclerosis
- No development reported Parkinson's disease
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in USA (PO, Capsule)
- 28 Jan 2023 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in USA (PO)
- 04 Jan 2023 Phase-I clinical trials in Amyotrophic lateral sclerosis in South Korea (unspecified route) (1st Biotherapeutics pipeline, January 2022)